| HORIZON | TRADES | WIN RATE | INSIDER RETURN | SPY RETURN | MEAN EXCESS | MEDIAN EXCESS | T-STAT |
|---|---|---|---|---|---|---|---|
| 7d | 6 | +33.33% | -0.53% | +0.96% | -1.50% | +1.19% | — |
| 14d | 6 | +50.00% | -1.92% | +0.43% | -2.35% | -0.29% | — |
| 30d | 6 | +50.00% | -1.90% | +1.70% | -3.59% | -4.74% | — |
| 60d | 6 | +83.33% | -15.76% | -1.86% | -13.90% | -13.80% | — |
| 90d | 6 | +50.00% | +26.90% | -1.92% | +28.82% | +24.91% | — |
| 180d | 6(2 pending) | +100.00% | -41.10% | +9.16% | -50.56% | -52.24% | — |
| 1y | 6(3 pending) | +100.00% | -36.22% | +20.32% | -56.53% | -49.48% | — |
| 2y | 6(5 pending) | +100.00% | -57.42% | +48.52% | -105.94% | -105.94% | — |
| COMPANY | TYPE | SHARES | PRICE | VALUE | HELD AFTER | TRADE DATE | FILED | DETAILS |
|---|---|---|---|---|---|---|---|---|
| APLS APELLIS PHARMACEUTICALS, INC. | PURCHASEGRANT Stock grant | 41,250 | — | — | 41,250 | May 14, 2026 | May 14, 2026 ↗ | View → |
| APLS APELLIS PHARMACEUTICALS, INC. | SALE Chief Medical Officer | 82,500 | — | — | 0 | May 14, 2026 | May 14, 2026 ↗ | View → |
| APLS APELLIS PHARMACEUTICALS, INC. | SALE Chief Medical Officer | 37,000 | — | — | 0 | May 14, 2026 | May 14, 2026 ↗ | View → |
| APLS APELLIS PHARMACEUTICALS, INC. | SALE Chief Medical Officer | 49,000 | — | — | 0 | May 14, 2026 | May 14, 2026 ↗ | View → |
| APLS APELLIS PHARMACEUTICALS, INC. | SALE Chief Medical Officer | 8,888 | — | — | 0 | May 14, 2026 | May 14, 2026 ↗ | View → |
| APLS APELLIS PHARMACEUTICALS, INC. | SALE Chief Medical Officer | 41,250 | — | — | 0 | May 14, 2026 | May 14, 2026 ↗ | View → |
| APLS APELLIS PHARMACEUTICALS, INC. | PURCHASEGRANT Stock grant | 26,396 | — | — | 26,396 | May 14, 2026 | May 14, 2026 ↗ | View → |
| APLS APELLIS PHARMACEUTICALS, INC. | SALE Chief Medical Officer | 29,696 | — | — | 0 | May 14, 2026 | May 14, 2026 ↗ | View → |
| APLS APELLIS PHARMACEUTICALS, INC. | SALE Chief Medical Officer | 26,396 | — | — | 0 | May 14, 2026 | May 14, 2026 ↗ | View → |
| APLS APELLIS PHARMACEUTICALS, INC. | SALE Chief Medical Officer | 12,723 | — | — | 0 | May 14, 2026 | May 14, 2026 ↗ | View → |
| APLS APELLIS PHARMACEUTICALS, INC. | SALE Chief Medical Officer | 86,525 | — | — | 0 | May 14, 2026 | May 14, 2026 ↗ | View → |
| APLS APELLIS PHARMACEUTICALS, INC. | SALEGRANT Gift | 900 | — | — | 86,525 | Apr 29, 2026 | May 1, 2026 ↗ | View → |
| APLS APELLIS PHARMACEUTICALS, INC. | SALE Chief Medical Officer | 2,797 | $21.77 | $60.9K | 86,527 | Jan 22, 2026 | Jan 23, 2026 ↗ | View → |
| APLS APELLIS PHARMACEUTICALS, INC. | SALE Chief Medical Officer | 1,882 | $19.79 | $37.3K | 89,324 | Jan 20, 2026 | Jan 21, 2026 ↗ | View → |
| APLS APELLIS PHARMACEUTICALS, INC. | SALE Chief Medical Officer | 3,020 | $25.53 | $77.1K | 91,206 | Jan 5, 2026 | Jan 6, 2026 ↗ | View → |
| APLS APELLIS PHARMACEUTICALS, INC. | PURCHASEGRANT Stock grant | 82,500 | $19.39 | $1.60M | 82,500 | Jun 9, 2025 | Jun 11, 2025 ↗ | View → |
| APLS APELLIS PHARMACEUTICALS, INC. | PURCHASEGRANT Stock grant | 39,594 | — | — | 93,301.37 | Jan 21, 2025 | Jan 21, 2025 ↗ | View → |
| APLS APELLIS PHARMACEUTICALS, INC. | SALE Chief Medical Officer | 1,853 | $29.96 | $55.5K | 53,707.37 | Jan 17, 2025 | Jan 21, 2025 ↗ | View → |
| APLS APELLIS PHARMACEUTICALS, INC. | SALE Chief Medical Officer | 2,816 | $33.81 | $95.2K | 55,560.37 | Jan 6, 2025 | Jan 8, 2025 ↗ | View → |
| APLS APELLIS PHARMACEUTICALS, INC. | PURCHASEGRANT Stock grant | 25,445 | — | — | 58,376.37 | Jan 16, 2024 | Jan 17, 2024 ↗ | View → |
| APLS APELLIS PHARMACEUTICALS, INC. | PURCHASEGRANT Stock grant | 37,000 | $66.30 | $2.45M | 37,000 | Jan 16, 2024 | Jan 17, 2024 ↗ | View → |
| APLS APELLIS PHARMACEUTICALS, INC. | SALE Chief Medical Officer | 2,751 | $60.05 | $165.2K | 32,931.37 | Jan 4, 2024 | Jan 5, 2024 ↗ | View → |
| APLS APELLIS PHARMACEUTICALS, INC. | PURCHASEGRANT Stock grant | 49,000 | $50.28 | $2.46M | 49,000 | Jan 3, 2023 | Jan 5, 2023 ↗ | View → |
| APLS APELLIS PHARMACEUTICALS, INC. | PURCHASEGRANT Stock grant | 35,549 | — | — | 35,682.37 | Jan 3, 2023 | Jan 5, 2023 ↗ | View → |